FIELD: medicine.
SUBSTANCE: invention relates to the application of pharmacologically acceptable salt of 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ole as an active ingredient in a drug for the prevention or treatment of brain atrophy, where the drug is injected to a patient with Alzheimer’s disease of mild and moderate severity, preclinical Alzheimer’s disease, prodromal period of Alzheimer’s disease or mild cognitive impairment caused by Alzheimer’s disease (MCI due to AD) daily at a dosage from 100 mg to 400 mg per one dosage of 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ole on injection.
EFFECT: obtaining a drug for the prevention or treatment of brain atrophy.
3 cl, 4 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG FOR PREVENTION OR TREATMENT OF TAUPATHY | 2018 |
|
RU2739199C1 |
| THERAPEUTIC INTERACTIONS OF LEUKOMETHYLTHIONINIUM | 2020 |
|
RU2834773C2 |
| MEMANTINE THERAPY FOR ALZHEIMER'S DISEASE OF LOW AND LOW TO MODERATE SEVERITY | 2005 |
|
RU2371173C2 |
| COMPOSITION CONTAINING ANTIBODY AGAINST ABETA PROTOFIBRILS AND INHIBITOR OF BETA-SECRETASE BACE1 FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2786476C2 |
| METHOD OF TREATING ALZHEIMER'S DISEASE THROUGH REGULATION OF INTESTINAL MICROORGANISMS | 2020 |
|
RU2810079C2 |
| METHOD OF IDENTIFYING PATIENT SENSITIVE TO MEDICINAL PRODUCT BASED ON MANNURONIC ACID OLIGOSACCHARIDES AMONG PATIENTS WITH ALZHEIMER'S DISEASE | 2020 |
|
RU2806017C2 |
| METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE BY T-CELL INHIBITION OF AMINO ACID UPTAKE | 2020 |
|
RU2791665C1 |
| METHOD OF TREATMENT OF ALZHEIMER'S DISEASE THROUGH REGULATION OF AMINO ACID LEVEL | 2020 |
|
RU2801150C1 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| FOOD COMPOSITION FOR PATIENTS SUFFERING FROM PRODROMAL DEMENTIA | 2008 |
|
RU2487557C2 |
